Magnevist® enteral (Gadopentetate) is a Gd-DTPA solution for use as a gastrointestinal contrast agent to visualize the bowel in MRI scans.

See also Positive Oral Contrast Agents and Gadopentetate Gastrointestinal.

Short name: Mn-DPDP
This MRI contrast agent is a chelate complex of the paramagnetic metal ion manganese (Mn) and fodipir. Mn-DPDP (Teslascan) shortens the longitudinal relaxation time and is used for the T1 weighted enhancement of MR images. Mangafodipir trisodium accumulates after intravenous injection in the healthy tissue of the liver and improves the detection, localization, characterization, and evaluation of lesions of the liver, pancreas, but can also be used in cardiac MRI.
See also Hepatobiliary Chelates and Teslascan®.
The United States Food and Drug Administration (FDA) has granted marketing clearance 1997, to Nycomed Amersham's MRI contrast medium. Nycomed/Amersham, now GE Healthcare markets the product under the trade name Teslascan®.

Porphyrins occur naturally in plants and animals. All porphyrin molecules feature an aromatic macrocycle ring with a central binding site. This site accommodates transition metals, which are held in place by inward-facing nitrogen atoms. Metalloporphyrins have usually a low toxicity and a potential of a selective uptake in tumors or necrosis. These properties are advantageous for a use as MRI tumor specific agents with positive enhancement. These contrast agents enhance tumors on T1 weighted sequences, which are isointense to surrounding tissues. Porphyrin-based compounds have also necrosis avid properties; they can depict the extent of myocardial infarction as defined by histopathology.
Metalloporphyrins are also used in photodynamic therapy of tumors. The compounds contain a 'lone star' metal atom at the center of the ring and are 'bigger than the average porphyrin'. They contain five N atoms in the central chelating core and this allows them to form complexes with large trivalent lanthanide metals, which have useful cancer therapy properties.

See also Classifications, Characteristics, etc., Gadophrin, MnIIITPPS4, Necrosis Avid Contrast Agent.

Many MR imaging techniques using Motion Probing Gradients (MPG's) such as Spin Echo (SE), Stimulated Echo (STE), Rapid Acquisition with Relaxation Enhancement (RARE), Turbo-SE, and SE-EPI (Echo Planar Imaging for Spin echo acquisition), Spiral imaging, and Projection reconstruction including PROPELLER are applicable to DWI. In diffusion weighted imaging, 2 MPG's are required. The MPG's are put symmetrically into both sides of a 180° or 90° RF pulse to change the direction of the magnetized spin in the X-Y plane for spin echo or stimulated echo acquisition.

MultiHance® is a paramagnetic contrast agent for use in diagnostic magnetic resonance imaging (MRI) of the liver and central nervous system. MultiHance® is a small molecular weight chelate, which tightly binds the Gd atom. The substance is excreted partly by the kidneys, partly by the biliary system, which is especially unique.
MultiHance® is indicated, for the detection of focal liver lesions in patients with known or suspected primary liver cancer (e.g. hepatocellular carcinoma) or metastatic disease.
MultiHance® is also indicated in brain MRI and spine MRI where it improves the detection of lesions and provides diagnostic information additional to that obtained with unenhanced MRI.
Gd-BOPTA-enhanced MRA can provide superior vascular signal intensity and SNR, as compared with Gd-DTPA, due to its higher relaxivity, even at lower doses.
1 ml of solution MultiHance® contains: (0.5M) gadobenate dimeglumine 529 mg = gadobenic acid 334 mg + meglumine 195 mg. Viscosity at 37°C: 5.3 mPa

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m²), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.